SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Parfitt AM 1993 Bone age, mineral density, and fatigue damage. Calcif Tissue Int 53 (Suppl 1):S82S85.
  • 2
    Schaffler MB, Choi K, Milgrom C 1995 Aging and matrix microdamage accumulation in human compact bone. Bone 17:521525.
  • 3
    Wenzel TE, Schaffler MB, Fyhrie DP 1996 In vivo trabecular microcracks in human vertebral bone. Bone 19:8995.
  • 4
    Burr DB, Forwood MR, Fyhrie DP, Martin RB, Schaffler MB, Turner CH 1997 Bone microdamage and skeletal fragility in osteoporosis and stress fracture. J Bone Miner Res 12:615.
  • 5
    Norman TL, Wang Z 1997 Microdamage of human cortical bone: Incidence and morphology in long bones. Bone 20:375379.
  • 6
    Fazzalari NL, Forwood MR, Smith K, Manthey BA, Herreen P 1998 Assessment of cancellous bone quality in severe osteoarthrosis: Bone mineral density, mechanics, and microdamage. Bone 22:381388.
  • 7
    Donahue SW, Galley SA 2006 Microdamage in bone: Implications for fracture, repair, remodeling, and adaptation. Crit Rev Biomed Eng 34:215271.
  • 8
    Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687694.
  • 9
    Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA the Alendronate Phase III Osteoporosis Treatment Study Group 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:11891199.
  • 10
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:10511056.
  • 11
    Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613620.
  • 12
    Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB 2001 Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524531.
  • 13
    Komatsubara S, Mori S, Mashiba T, Li J, Nonaka K, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H 2004 Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 19:9991005.
  • 14
    Komatsubara S, Mori S, Mashiba T, Ito M, Li J, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H 2003 Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18:512520.
  • 15
    Allen MR, Iwata K, Phipps R, Burr DB 2006 Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39:872879.
  • 16
    Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, Fahrleitner-Pammer A, Petto H, Westmore M, Michalsky D, Sato M, Dobnig H 2007 Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 41:378385.
  • 17
    Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N, Delmas P 2007 Microcracks Frequency and Bone Remodeling in Postmenopausal Osteoporotic Women on Long-Term Bisphosphonates: A Bone Biopsy Study. J Bone Miner Res 22:15021509.
  • 18
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:14341441.
  • 19
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Recombinant human parathyroid hormone (1–34 [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:19321941.
  • 20
    Dobnig H, Sipos AA, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC, Pavo I, Wang J, Eriksen EF 2005 Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:39703977.
  • 21
    Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, Cruz JD, Nieves JW, Dempster DW 2006 A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: Early actions of teriparatide. J Bone Miner Res 21:366373.
  • 22
    Mashiba T, Hui S, Turner CH, Mori S, Johnston CC, Burr DB 2005 Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs. Calcif Tissue Int 77:180185.
  • 23
    Chavassieux PM, Ariot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:14751480.
  • 24
    Schaffler MB 2003 Role of bone turnover in microdamage. Osteoporos Int 14 (Suppl 5):S73S80.
  • 25
    Li J, Mashiba T, Burr DB 2001 Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 69:281286.
  • 26
    Li J, Sato M, Jerome C, Turner CH, Fan Z, Burr DB 2005 Microdamage accumulation in the monkey vertebra does not occur when bone turnover is suppressed by 50% or less with estrogen or raloxifene. J Bone Miner Metab 23:S48S54.
  • 27
    Allen MR, Burr DB 2007 Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22:17591765.
  • 28
    Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP 2000 Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:30693076.
  • 29
    Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550555.
  • 30
    McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:17621768.
  • 31
    Ettinger B, San Martin J, Crans G, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745751.
    Direct Link:
  • 32
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ PaTH Study Investigators 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:12071215.
  • 33
    Marcus R, Wang O, Satterwhite J, Mitlak B 2003 The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:1823.
  • 34
    Burr DB 2005 Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size. Curr Osteoporos Rep 3:1924.
  • 35
    Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF 2006 Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 21:855864.
  • 36
    Paschalis EP, Glass EV, Donley DW, Eriksen EF 2005 Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: New results from the fracture prevention trial. J Clin Endocrinol Metab 90:46444649.
  • 37
    Masse P, Rimnac C, Yamauchi M, Coburn P, Rucker B, Howell S, Boskey A 1996 Pyridoxine deficiency affects biomechanical properties of chick tibial bone. Bone 18:567574.
  • 38
    Allen MR, Reinwald S, Burr DB 2008 Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Int 82:354360.
  • 39
    Li J, Burr DB, Stepan JJ, Dobnig H, Fahrleitner-Pammer A, Sipos A, Mullarney T, Westmore M, Sato M, Pavo I 2007 Teriparatide improves bone microarchitecture in postmenopausal women previously treated with alendronate. J Bone Miner Res 22:S1 ; S28.
  • 40
    Courtney AC, Hayes WC, Gibson LJ 1996 Age-related differences in post-yield damage in human cortical bone. Experiment and model. J Biomech 29:14631471.
  • 41
    Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV 2008 Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852860.
  • 42
    Arlot ME, Burt-Pichat B, Roux JP, Vashishth D, Bouxsein ML, Delmas PD 2008 Microarchitecture influences microdamage accumulation in human vertebral trabecular bone. J Bone Miner Res 23:16131618.